glp-1 news october 1 2025 obesity drug today Right now, Maryland Medicaid does NOT cover the new class of GLP-1 medications for obesity—despite their proven effectiveness. "The reason why we hear so much 2025 dominates for GLP-1 trial
Description
UK guidance included.
What does evidence say about GLP-1 agonists and suicidal ideation
A new case report highlights the potential risk of "anhedonia" from high doses of tirzepatide, though it can be treated effectively.
Tirzepatide prescriptions are available online for weight loss at Klinic
Trail registration Study registered in clinicaltrials.org with the identifier NCT05535322.
Dulaglutide is a long-acting GLP-1 receptor agonist used for type 2 diabetes and weight management
